iCardiac acquires Longmont-based nSpire Health’s clinical-trials division

LONGMONT — The clinical-trials division of Longmont-based nSpire Health Inc. has been acquired by iCardiac Technologies, based in Rochester, N.Y.

iCardiac, a provider of cardiac safety assessment services to the pharmaceutical industry, has opened an office in Longmont to accommodate the project-management, data-management, customer-support, information-technology, technology-development and business-development teams that are joining iCardiac from nSpire Health.

Financial terms of the deal were not disclosed, and the acquisition is effective immediately.

Formed in late 2006 in Louisville after a team of private investors acquired Louisville-based Ferraris Respiratory, nSpire Health moved its headquarters to 74,800 square feet of leased space at 1830 Lefthand Circle in the Campus at Longmont in 2007. The company develops respiratory information systems software and respiratory medical devices. Since its founding, nSpire Health has conducted more than 225 clinical trials, providing centralized spirometry, pulmonary diagnostics, challenge testing, eDiary and data-management services for Phase I through Phase IV studies. It has worked with more than 5,400 investigative sites in 55 countries.

“iCardiac and nSpire have worked side-by-side as closely integrated partners for over five years and on over 20 clinical trials,” said Alex Zapesochny, president and chief executive of iCardiac, in a media release. “That working relationship confirmed for us that the people, solutions and technologies of nSpire are second to none. It also made the decision to join forces with nSpire’s clinical trials division an easy one, as iCardiac sought to expand our capabilities to better serve the growing demand for respiratory and inhaled therapeutics programs for asthma, COPD, cystic fibrosis and other indications.”

John Sage, who served as senior vice president of nSpire Health’s clinical division and will continue to lead respiratory and ePRO service operations at iCardiac, said customers will experience numerous advantages and efficiencies from sourcing their cardiac-safety, respiratory and ePRO services all from the same vendor.

With the sale of its clinical-trials division, nSpire Health will focus on developing and expanding its commercial health-care business and also will serve as an equipment supplier to iCardiac for clinical trials applications.

Also launched in 2006, iCardiac uses its tools and processes to determine whether new drugs and medical devices have cardiac side-effects.